Transurethral enucleation of the prostate for treatment of benign prostatic hyperplasia in patients less than 50 years old.
- Author:
Ya-wen XU
1
;
Chun-xiao LIU
;
Shao-bo ZHENG
;
Hu-ling LI
;
Ping FANG
;
Bin-shen CHEN
;
Kai XU
;
Hai-yan SHEN
Author Information
- Publication Type:Journal Article
- MeSH: Humans; Male; Middle Aged; Prostate; surgery; Prostatic Hyperplasia; surgery; Transurethral Resection of Prostate; methods; Treatment Outcome
- From: Journal of Southern Medical University 2010;30(12):2708-2710
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the therapeutic effect of transurethral enucleation of the prostate for treatment of benign prostatic hyperplasia in patients below 50 years of age.
METHODSTwelve patients with benign prostatic hyperplasia patients (mean age 48.2 years, range 46-49 years) underwent transurethral enucleation of the prostate. The middle lobe and two lateral lobes were enucleated with the preprosthetic sphincter and anterior fibromuscular stroma preserved during the operation. The patients were followed up to evaluate the lower urinary tract symptoms and sexual activity after the surgery.
RESULTSThe 12 patients were followed up for 3 to 6 months. The symptoms of lower urinary tract obstruction were improved obviously after the surgery, and the International Prostate Symptom Score (IPSS) decreased from 24±5.1 to 8.8±1.4 and peak urine flow rate (Qmax) increased from 8.1±4.2 ml/s to 20.1±4.2 ml/s at 3 months postoperatively. All the 12 cases had residual urine (12-44 ml) preoperatively, but after the surgery, only 4 still had residual urine of less than 30 ml. All the patients had normal erection function postoperatively, and 10 had normal ejaculation; the other 2 patients recovered normal ejaculation 3 and 5 months after the operation, respectively.
CONCLUSIONSTransurethral enucleation can alleviate the low urinary tract obstruction symptom and improve the sexual function by avoiding preprosthetic sphincter injury in relatively young patients with benign prostatic hyperplasia.